Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Alfa Cytology specializes in providing comprehensive ADME (Absorption, Distribution, Metabolism, and Excretion) evaluation services specifically tailored for breast cancer drugs. Our expertise and state-of-the-art facilities enable us to deliver reliable data and insights to support the development and optimization of novel therapeutics targeting breast cancer.
CDK4/6 inhibitors are established drugs for the treatment of advanced and metastatic breast cancer. ADME studies are critical in the CDK4/6 inhibitors development process for breast cancer. In breast cancer drug discovery, understanding the ADME properties of drugs can help optimize routes of administration and dosage forms to improve drug bioavailability and therapeutic efficacy in the body.
Fig.1 Pharmacokinetics of CDK4/6 Inhibitors in Breast Cancer Treatment. (Roncato R, et al., 2020)
ADME testing and analysis are crucial for identifying the ADME characteristics and potential drug-drug interactions of pharmaceutical compounds. Alfa Cytology provides comprehensive services to identify the absorption, distribution, metabolism, and excretion properties, aiding in the de-risking of candidate molecules.
The movement of drugs from the administration site to the bloodstream is associated with absorption. We offer drug solubility determination services to assess the bioavailability of your compound. Additionally, we provide services for measuring lipophilicity to investigate whether the compound is stored in lipid regions and its degree of binding to target proteins.
The efficacy of a drug depends on the concentration of the free drug, rather than the total concentration in the plasma. Therefore, the testing services we provide will assist you in accomplishing this task. We utilize Rapid equilibrium dialysis to test the binding of compounds to plasma proteins and determine the degree of compound-protein binding in plasma.
The subcellular fraction of liver, namely microsomes, is utilized to investigate the metabolic fate of drugs. We conduct early-stage plasma stability surveys during the drug discovery process to assess potential degradation and/or protein binding issues. You can utilize the drug metabolism data we provide to assess the potential safety or toxicity of the drug.
Excretion is the process by which metabolized drug compounds are eliminated from the body. With our customized services, you can determine the rate of drug excretion and the routes through which drugs are eliminated. By analyzing metabolites in feces and urine, we can determine the contribution of the liver and kidneys to drug excretion.
Alfa Cytology provides you with reliable ADME evaluation services. Contact us today to discuss your ADME evaluation needs and how we can assist you in advancing your breast cancer drug development program.
Reference